Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM. N ...
A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection
Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, Himansu S, Diamond MS, Crowe JE Jr. Sci Immunol. 2019 May 17;4(35). PubMed
Structure and Degradation of Circular RNAs Regulate PKR Activation in Innate Immunity
Liu CX, Li X, Nan F, Jiang S, Gao X, Guo SK, Xue W, Cui Y, Dong K, Ding H, Qu B, Zhou Z, Shen N, Yang L, Chen LL. Cell. 2019 May 2;177(4):865-880.e21. PubMed
Uptake and Fate of Fluorescently Labeled DNA Nanostructures in Cellular Environments: A Cautionary Tale
Lacroix A, Vengut-Climent E, de Rochambeau D, Sleiman HF. ACS Cent Sci. 2019 May 22;5(5):882-891. PubMed
Nonviolent Self-Catabolic DNAzyme Nanosponges for Smart Anticancer Drug Delivery
Wang J, Wang H, Wang H, He S, Li R, Deng Z, Liu X, Wang F. ACS Nano. 2019 May 28;13(5):5852-5863. PubMed
Guidelines for Experiments Using Antisense Oligonucleotides and Double-Stranded RNAs
Gagnon KT, Corey DR. Nucleic Acid Ther. 2019 Mar 23. Keith T. Gagnon David Corey In addition to the widespread use of synthetic oligonucleotides to manipulate RNA levels in basic research, interest in oligonucleotide ...
Advances in SELEX technologies for aptamer selection
Presenter: Günter Mayer, University of Bonn, Germany Date: August 27, 2019 Description: Aptamers are short single-stranded oligonucleotides, selected to interact with target molecules with high affinity and specificity. These characteristics and their versatile applicability, make aptamers universal molecular probes in biotechnological and therapeutic applications. ...
Interview with Kalyan Dulla, PhD, MBA
Kalyan Dulla, PhD, MBA Director Non-Clinical Research ProQR Therapeutics How did you become interested in the field of oligonucleotides? Although I had been aware of the use of antisense oligonucleotides for (m)RNA knockdown or as aptamers since my university days I was not ...
